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Highlights 
• Adenovirus (AdV) vectors are used in vaccine development and gene therapy.
• The common process involves the production of research virus seed stocks (RVSS) and
master virus seed stocks (MVSS) via CsCl density gradient centrifugation or
chromatographic columns. The AdV produced has reduced infectivity, limited long
term storage capability and reduced yields due to column blockage.
• The PEG600/(NH4)2SO4 aqueous two-phase system (ATPS) is a rapid, simple
alternative to generate purer and highly infectious AdV RVSS directly from cell lysates
that are highly suited to MVSS production.
• ATPS produced RVSS also show excellent in vitro and in vivo efficacy for direct
research applications.
• The AdV produced can also be frozen or refrigerated for over 2 years, avoiding disposal
of unused RVSS and enabling its long-term storage and use.
© 2021 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of an article which has been published 




Adenoviruses (AdVs) are used as gene therapy vectors to treat human diseases and as 
vaccines against COVID-19. AdVs are produced by transfecting human embryonic kidney 
239 (HEK293) or PER.C6 virus producer cells with AdV plasmid vectors or infecting these 
cells with cell lysates containing replication-defective AdV. Cell lysates can be purified 
further by caesium chloride or chromatographic protocols to research virus seed stocks 
(RVSS) for characterisation to high quality master virus seed stocks (MVSS) and working 
virus seed stocks (WVSS) before downstream production of pure, high titre AdV. Lysates 
are poorly infectious, block filtration columns and have limited storage capability. Aqueous 
two-phase systems (ATPS) are an alternative method for AdV purification that rapidly 
generates cleaner RVSS for characterisation to MVSS. After testing multiple ATPS 
formulations, an aqueous mixture of 20% PEG600 and 20% (NH4)2SO4 (w/w) was found 
most effective for AdV partitioning, producing up to 97 + 3% yield of high-titre virus that 
was devoid of aggregates both effective in vitro and in vivo with no observable cytotoxicity. 
Importantly, AdV preparations stored at -200C or 40C show negligible loss of titre and are 
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1. Introduction  
Adenoviruses (AdVs) are highly suited to effective gene transfer and commonly used in 
vaccine production to target both dividing and non-dividing cells and their biology is well 
understood (Cortin, Thibault et al. 2004; Ura, Okuda et al. 2014). The viruses replicate and are 
assembled within the nucleus of infected cells before undergoing lysis for the progeny virus to 
infect adjacent cells. AdV particles have a diameter of 90 - 110 nm containing capsid proteins 
and fibres making up their structure surrounding a linear double-stranded DNA genome 
 
(Russell 2009). Seven AdV species (A-G) are known, which have been subdivided into 57 
serotypes. Ad serotype 5 (AdV5) is the most commonly used for gene therapy with fibre 
proteins that bind coxsackievirus and adenovirus (CAR) receptors on permissive cells 
(Bergelson, Cunningham et al. 1997; Roelvink, Lizonova et al. 1998; Kirby, Lord et al. 2001,) 
and an RGD motif that binds to the cell surface integrins for cell entry (Huang, Kamata et al. 
1996; Davison, Diaz et al. 1997). AdV5 usually elicits a significant host immune response due 
to recognition of virus proteins by T lymphocytes and neutralising antibodies (Gilgenkrantz, 
Duboc et al. 1995; Yang, Su et al. 1996). 
AdV vectors are designed to carry a large transgene payload and particles are usually 
produced at high titre from human embryonic kidney 293 (HEK293) or PER.C6 producer cells 
(Xie, Pilbrough et al. 2002). For therapeutic applications, replication-defective vectors, 
originally based on AdV5, have been generated. First generation vectors have early genes E1 
and/or E3 regions removed allowing ~8kb of transgenic sequences to be carried. These early 
genes that are necessary for virus replication have been inserted into the producer cells to 
compliment transfection or infection of defective vector genomes into these cells to enable the 
generation of attenuated progeny virus particles (Fallaux, Kranenburg et al. 1996; Graham, 
Smiley et al. 1977; Fallaux, Bout et al. 1998). Due to the immune response caused by 1st 
generation AdV5, second generation vectors have been developed with further deletions of 
E2A, E2B and E4 genes with larger transgene capacity (Bischoff, Kirn et al. 1996; Fallaux, 
Kranenburg et al. 1996,). Third generation vectors have all internal components removed, 
except replication origins and packaging signals leaving the 3’ and 5’ inverted terminal repeats 
(ITR) remaining and therefore require complementation with helper viruses. AdVs have also 
been engineered as conditionally replicative carrying mutated E genes that only allow 
replication in cells not expressing P53 or Rb proteins and so are suited to cancer gene therapy 
(Bischoff, Kirn et al. 1996). AdV vectors can therefore infect cells efficiently but are not able 
to replicate due to deletions of wild type genes.  
Human and chimpanzee AdV based vaccines of various sorts have entered human trials 
against HIV, influenza, Ebola, tuberculosis, and malaria diseases. Natural wild type infection 
by AdV is common in humans and thus hAdV5 vaccines are recognised by pre-existing anti-
hAdV5 antibodies in humans (Xiang, Gao et al. 2003; Liebowitz, Lindbloom et al. 2015). As 
a result of this, alternative serotypes have been used or AdV from alternative species such as 
the chimpanzee and gorilla (Cheng, Wang et al. 2015; Baden, Liu et al. 2015; Bos, Rutten et 
 
al. 2020; Capone, Raggioli et al. 2020; Folegatti, Ewer et al. 2020; Zhu, Li et al. 2020). 
Currently, these AdVs are in clinical trials to combat the COVID-19 pandemic. 
To obtain large-scale good manufacture practice-certified (GMP) vector preparations 
at high titre, fed-batch cultures of anchorage independent cells are grown in serum-free 
suspension bioreactors with improved culture conditions for optimal growth density (Lesch, 
Heikkila et al. 2015).  
AdV production to clinical grade by adherent or suspension culture producer cells 
requires both up and downstream manufacturing processes that are time consuming, costly and 
difficult to scale up, thereby limiting AdV manufacture. AdV production requires producer cell 
plasmid transfection or infection with crude cell lysates containing AdV particles. This 
produces research virus seed stocks (RVSS) that are characterised to become master and 
working virus seed stocks (MVSS and WVSS). After infection and cell lysis, AdV particles 
can be subjected to CsCl density separation to remove producer cell genomes and proteins to 
generate pure AdV. Both the use of cell lysates and CsCl purification have limitations. Cell 
lysates have reduced infectivity and can block purification columns used in downstream 
processing, thereby reducing particle yield. CsCl Ad production avoids this but requires two 
rounds of ultracentrifugation, which not only significantly contributes to the lengthy time 
required for AdV preparation but also results in loss of infectious particles during the extraction 
process. Although automated continuous flow centrifugation can be easily scaled up  for 
laboratory use, the need for dialysis to remove this toxic salt adds further cost, time (10 h) and 
reduces yield. It can also result in particle aggregation that reduces viable infectious titre 
(Boychyn, Yim et al. 2001; Farid 2007; McNally, Darling et al. 2014). The use of 
chromatography to purify lysed cell samples over packed columns also limits supernatant 
volumes that can be used, and columns can become clogged resulting in a low AdV yield 
(McNally, Darling et al. 2014). Importantly, robust, high-quality, characterised MVSS and 
WVSS are required for downstream processing to clinical grade virus. At the upstream stage, 
a method that could cost effectively improve the purity of the Ad starting material from crude 
cell lysates and match that of CsCl purification rapidly whilst avoiding early stage 
chromatography to provide RVSS would be highly beneficial to Ad production.  
Aqueous two-phase systems (ATPS) have been shown to be successful in purifying 
rapidly several types of biomolecules, including proteins, using immiscible liquids as phases 
for separation (Albertsson, Andersson et al. 1982; Chao, Shum, 2020). ATPS offers a simple, 
rapid and promising alternative methodology for the rapid scale-up of vector preparations, 
 
whilst retaining particle infectivity and titre. This can streamline the production of RVSS 
further for downstream applications. Polyethylene glycol (PEG) is especially useful in 
separating biomolecules and its hydrophobicity is directly correlated to its molecular weight. 
When PEG is combined with a kosmotropic salt, such as in the PEG300-phosphate ATPS, AdV 
can be purified in the upper aqueous phase, whilst remaining highly infectious (Negrete, Ling 
et al. 2007a; Negrete, Ling et al. 2007b). Dextran and methylcellulose/polyethylene glycol 
polymers can also be used to generate viable virus particles that are concentrated (up to 1000-
fold) using low speed short centrifugation times. ATPS purification has also been applied 
successfully to adeno-associated virus (AAV) vector production using 10% PEG8000/13.2% 
(NH4)2SO4 solutions that gently remove impurities and avoids dialysis to a level acceptable for 
in vivo gene transfer (Rogers, Bond et al. 1996; Guo, Xiao et al. 2013;). Importantly, ATPS is 
cost effective and can be easily performed in any laboratory without the need for expensive 
equipment (Molino, Lopes et al. 2018). These demonstrate advantages of the ATPS for 
purification of vectors compared to CsCl or chromatographic protocols. 
This work applies ATPS technology to generate RVSS of AdV vectors at reduced cost 
and time with high particle yield, purity and infectivity. Several immiscible liquid compound 
formulations will be screened for partitioning AdV particles from infected HEK293T producer 
cell lysates, their infectivity and potential toxicity in vitro. The ATPS formulation that shows 
the highest vector recovery will also be applied in vivo to compare CsCl and ATPS purified 
AdV to ensure comparable levels of gene transfer and potential toxicity in vivo. Because ATPS 
technology is amenable to scale-up, we propose this technology ideal for the rapid manufacture 
of large amounts of RVSS for characterisation to MVSS under GMP conditions to support 
clinical grade therapeutic AdV and AdV-based vaccines.  
 
 
2. Material and Methods 
2.1. Cell culture 
Phosphate buffered saline (PBS) solution (Fisher Scientific, Loughborough) was 
prepared in 500ml batches with sterile dH2O and autoclaved. Cells were cultured in complete 
medium prepared using Dulbecco’s Modified Eagle Medium (DMEM) GlutaMAX™ 
supplemented with 1% penicillin-streptomycin and 10% fetal bovine serum (all reagents are 
purchased Fisher Scientific). 0.05% trypsin (Fisher Scientific) diluted in PBS was used to 
detach cells from their substratum. All reagents used showed low levels of endotoxins present 
 
and are cGMP compatible. IMRS2, HEK293T and HepG2 cells were obtained from ATCC 
(Middlesex, UK). These were thawed and centrifuged at 1500 rpm for 5 minutes to pellet 
cells that were resuspended in 10ml complete medium. Cells were incubated at 37°C in the 
presence of 5% CO2 and the medium changed every 2 days. Cells were passaged when 
reaching 70%-80% confluency. 
 
2.2. Generation of adenovirus vectors 
For this study, 1st generation human AdVRSVβgal or AdVCMVLuc (E1 and E3 regions 
deleted), which drive the β-galactosidase or luciferase genes by the RSV and CMV promoters 
respectively, were generated using HEK293T cells. 1.5 x 107 cells grown in T175 culture flasks 
were infected with AdV (MOI of 10) for 72 hours. Cells were mechanically detached from the 
flasks and pelleted at 1500rpm for 10 minutes, followed by resuspension in 10ml complete 
medium. Cells were subjected to 3 freeze thaw cycles between 37°C and -80oC and cell debris 
pelleted by centrifugation at 1500rpm for 15 minutes. AdV was purified using high-speed CsCl 
density gradient ultracentrifugation and AdV particle concentration determined via OD260nm 
equivalent to AdV titre, for vector genomes and plaque assays on HEK293T cells respectively, 
as previously described (Fallaux, Bout et al. 1998). AdV was also recovered via ATPS 
partitioning from freeze thawed HEK293T cell batches (see below). AdRSVβgal and 
AdCMVLuc recovered by CsCl partitioning were tested on HeLa cells for infectivity via Xgal 
staining for β-galactosidase or luciferase gene expression via D-luciferin light emission, 
respectively.  
2.3. Analysis of AdV vectors for infectivity and replication incompetence 
To investigate for the presence or absence of replication competent adenovirus (RCA), 
infected Hela cells were cultured for a further 2 weeks after which time conditioned 
supernatants were filtered and then applied to fresh HeLa and HEK293T cells. These cells were 
stained using X-gal for β-galactosidase gene expression or tested for luciferase gene expression 
after 48hrs to indicate the presence of positively or negatively infected cells, as previously 
described (Clifton 2012). No cells were stained positive (i.e., blue or emitting light) indicating 
replication incompetence of AdV. 
 
2.4. Generation of ATPS phases and analysis of yield 
Polymers and salts were weighed and dissolved in deionised water at 37°C, 1.0MΩcm-
1 (Purite, Thames). Each system was vortexed, then left to separate at room temperature for 15 
 
mins (Table 1). ATPS created were: 14%/14% (w/w) PEG1000/K2HPO4, 14%/14% (w/w) 
(C6H10O6)n/PEG8000, 14%/14% (w/w) PEG8000/HNa2O4P, 14%/14% (w/w) 
PEG8000/K2HPO4, 14%/14% (w/w) PEG600/(NH4)2SO4, 20%/20% (w/w) 
PEG600/(NH4)2SO4, 14%/14% (w/w) UCON3900/Na2HPO4, 14%/14% (w/w) 
UCON970/Na2HPO4, 14%/14% (w/w) UCON970/C6H5Na3O7∙2H2O (Fisher Scientific & 
Sigma- Aldrich). ATPS consisting of 14% /14% (w/w) PEG8000/HNa2O4P, 14%/14% (w/w) 
PEG600/(NH4)2SO4, 14%/14% (w/w) UCON3900/Na2HPO4, 14%/14% (w/w) 
UCON970/Na2HPO4 were not used due to the formation of crystal salts.  
To assess the yield of vector recovery after ATPS, 10µl containing 3.5 x 1012 IU of 
AdVRSVβgal purified using CsCl gradient centrifugation was added to a 1:1 ratio of mixed 
upper and lower ATPS phases (2ml total). After gentle mixing, the phases were centrifuged at 
1500 rpm for partitioning for 15 minutes. Each layer was then quantified for AdVRSVβgal 
concentration by spectrophotometry at an optical density reading of 260nm for vector genomes 
(vg) equating to vector particles per ml (vp/ml) to calculate recovery yield using NanoDropTM 
2000C (Mittereder, March et al. 1996). This process was repeated thrice. Recovery was also 
measured by infection assays on HepG2 cells.  
AdV batches were also screened for aggregation as previously described (Lefesvre, van 
Bekkum 2003). Briefly, spectrophotometric ratios from 320/260 and 340/260 readings were 
assessed and no ratios above 0.3 were found indicating no virus aggregation. 
 
2.5. Infection and cytotoxicity assays of HepG2 and IMRS2 cell lines 
HepG2 (liver) and IMRS2 (neuronal) cells were cultured in 12 well dishes at 2 x 105 cells/well 
and incubated at 37°C with 5% CO2 for 24 hours. HepG2 cells have been shown to be highly 
permissive to AdV infection (Pan, Wu et al. 2012). 10µl of the upper and lower phases of each 
phase system containing purified AdVRSVβgal were then added to each well for 24 hours 
before replacing medium. 48 hours post infection, cells were stained for LacZ expression to 
determine the most effective ATPS for AdV purification, as previously described (Clifton 
2012). Cell viability was analysed via trypan blue exclusion 48 hours post AdVRSVβgal 
infection, where live cells exclude dye as opposed to dead cells that do not.  
 
2.6. Animal procedures 
Outbred male and female CD1 mice were used in this study (Charles River, Oxford). 
All animal experiments conducted within this study were in agreement with the United 
 
Kingdom Home Office guidelines, approved by the ethical review committee and following 
the institutional guidelines at University College London. To test hAdV gene transfer in vivo, 
AdVCMVLuc vector that drives luciferase gene expression from the CMV promoter was 
generated by infection of HEK293T cells followed by purification via 20%/20% (w/w) 
PEG600/(NH4)2SO4 ATPS. Purified vector from supernatant was titrated at 2.9 x 1013 vector 
genomes/ml via spectrophotometry. Healthy CD1 mice were anaesthetised with isoflurane with 
100% oxygen (Abbott Laboratories, London, UK) in a heated chamber at 37°C. A volume of 
100µl containing 1 x 109 vector genomes/ml AdVCMVLuc particles was administered to each 
the adult mice via tail vein intravenous injection. After the injections, mice were allowed to 
recover fully before being returned to their cages. 
 
2.7. Whole-body bioluminescence imaging  
Mice were anaesthetised with isoflurane with 100% oxygen and given an 
intraperitoneal injection of 15 mg/mL of D-luciferin (Gold Biotechnologies, ST Louis, USA). 
Mice were imaged after 5 minutes using a cooled charged-coupled device camera, (IVIS 
machine, Perkin Elmer, Coventry, UK) for between 1 second and 5 minutes. The regions of 
interest (ROI) were measured using Living Image Software (Perkin Elmer, Beaconsfield) and 
expressed as photons per second per centimetre squared per steradian (photons/second/cm2/sr). 
 
2.8. Statistical analysis 
Various replicates were used for treatments. ATPS formulations, genome recovery, IMRS2 
cell infection, HepG2 infection using AdV purified direct from HEK293T cell lysates and in 
vivo infections of purified AdV were all performed in triplicate. CsCl purified AdV partitioned 
via ATPS infection of HepG2 cells were performed five times and viability measured from 
treated cells were performed at minimum four times. Significant differences between 
treatments were derived using a Man Whitney U statistical test, with a P value cut off of 0.05 
for all data sets. 
 
3. Results 
3.1. hAdV genome recovery and infectivity following ATPS partitioning  
Of the 9 ATPS screened, 5 formulations provided virus recovery, of which the 3 most 
optimal yields were 75 ± 8.55% for 14%/14% (w/w) PEG1000/K2HPO4, 47 ± 5.94% for 
14%/14% (w/w) PEG8000/K2HPO4 and 83 ± 5.99% for 20%/20% (w/w) PEG600/(NH4)2SO4 
 
ATPS (Table 1). Vector partitioning was mainly restricted to upper phases. The vector titre 
reached for these ATPS ranged from 1.6 x 1012 to 2.9 x 1012 vg/ml (Table 2). 
 
Table 1. ATPS solutions tested for the purification of AdVRSVβgal particles. Successful 
(+) and unsuccessful (-) ATPS solutions for AdV purification are shown for each ATPS tested. 
All solutions are at 14%/14% (w/w) unless otherwise stated. Initial Ad input for purification 
was 3.5 x 10
12 
particles/ml. To detect for the presence or absence of viral nucleic acids and 
proteins, Abs260nm readings of the upper phase of each ATPS were measured after purification 
using NanoDrop
TM 
2000C. Negligible concentrations of AdV was present in the lower phases 
(n = 3). 
 
 
Table 2. AdVRSVβgal genome recovery after separation by ATPS. An initial input of 3.5 
x 10
12
 Ad vg/ml were separated in PEG1000/K2PO4, PEG8000/K2PO4 and 
PEG600/(NH4)2SO4. Abs260nm readings were averaged and corrected over a range of dilutions. 
 
AdV genome titre (vg/ml) was calculated by multiplying the average Abs260nm value by 1.1 
and the product by 10
12
 (n = 3) (Fallaux, Bout et al. 1998). 
To examine the infectivity of AdVRSVβgal partitioning to each phase, samples from 
both upper and lower phases were used to infect HepG2 cells, (Pan, Wu et al. 2012). Negligible 
HepG2 gene transfer was detected after exposing cells to any ATPS lower phases. 
Quantification of percentage infection by AdVRSVβgal, recovered through upper phase, was 
55.2 ± 2.7% for PEG1000/K2HPO4, 59.9 ± 9.8% for PEG8000/K2HPO4 and 97 ± 3% with 
PEG600/(NH4)2SO4 ATPS is shown in (Figure 1b).  
The IMRS2 neuronal cell line, which is of non-liver origin was also used as an 
alternative cell line to determine the efficacy of AdV infection. To measure IMRS2 
permissiveness to AdV infectivity, cells were exposed to 1011 - 106 CsCl purified AdV (Figures 
2a and 2b). Cell infection was observed as 100 ± 0% (1011), 80 ± 3.84% (1010), 60 ± 1.15% 
(109), 46 ± 2.19% (108), 15 ± 1.76% (107) and 1 ± 0.88% (106) using serial dilutions of AdV. 





Figure 1. Infection of HepG2 cells by AdVRSVβgal. (a). HepG2 infection by CsCl 
prepared vector after partitioning by 3 ATPS formulations. Positive staining for β-
galactosidase activity was identified in each ATPS upper phase, with highest infection by 
PEG600/(NH4)2SO4. Uninfected HepG2 cells appear negative for enzyme activity. (b). 
Quantification of cell infection: PEG1000/K2HPO4; 55.15 ± 2.74%, PEG8000/K2HPO4; 
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Figure 2. Analysis of IMRS2 cell permissiveness to AdVRSVβgal infection. (a). Infected 
IMRS2 cells at various dilutions of AdV particles (vg/ml). Infection was detected by analysis 
of β- galactosidase activity demonstrating IMRS2 cells are highly permissive to infection. 
(b). Quantification of positive cells after exposure to serial dilutions of CsCl prepared 
AdRSVβgal. IMRS2 infection was:  10
11




















1 ± 0.88% (n = 3).  
 
 
3.2. Isolation of Ad directly from 293T producer cell lysate 
The potential of ATPS to partition AdVRSVβgal directly from infected HEK293T cell 
lysates was assessed. HEK293 cells have previously been reported to produce high titre 
 
recombinant Ad virus (Wei, Fan et al. 2017; Chen, Wu et al. 2018). 293T producer cells were 
infected with CsCl purified AdRSVβgal seed stock at a MOI of 10. After producer cell 
infection, cells were isolated from culture flasks and subjected to freeze thaw cycles for 
partitioning through each of the 3 ATPS. These products can be RVSS or stocks generated 
using cGMP grade reagents for characterisation to MVSS. HepG2 and IMRS2 cells were 
infected and cells positive for β-galactosidase gene expression were counted. HepG2 and 
IMRS2 infection was 93.3 ± 0.9% versus 85.3 ± 1.8% using PEG1000/K2HPO4, 91.7 ± 2.4% 
versus 30 ± 1.2% using PEG8000/K2HPO4. 91.3 ± 1.5% versus 93.7 ± 2.2% infection was 
observed with PEG600/(NH4)2SO4, closely matching that of percentage infection using CsCl 
purified AdVRSVβgal partitioned through ATPS (Figures 3a and 3b). Contaminating proteins 
can be detected via spectrophotometry (Glasel 1995, Goldfarb, Saidel et al. 1951). All 
Abs260nm/280nm in ATPS purified AdV direct from cell lysates are above 0.6. Further HPLC 
analysis of ATPS purified AdV showed contaminating proteins present but to a lower extent 
that in crude lysates (data not shown). This demonstrates successful partitioning of AdV into 
the upper phase of ATPS, with the highest recovery using the PEG600/(NH4)2SO4 system. 
 
3.3. Cell survival following infection by AdRSVβgal recovered from ATPS formulations  
HepG2 cell survival was quantified using AdV after ATPS treatment and AdV infection 
(Figure 3a). We found HepG2 viability after AdVRSVβgal infection and gene transfer was 
similar between vector separated via ATPS from CsCl isolation or direct from HEK293T cell 
lysates. Cells showed between 77.33 ± 5.06% and 93.25 ± 0.63% viability with 
PEG1000/K2HPO4 treatments. PEG8000/K2HPO4 treatments showed between 87.25 ± 4.40% 
and 92.20 ± 2.99% viability. PEG600/(NH4)2SO4 treatments showed a viability of between 
83.75 ± 4.12% and 93.50 ± 0.99% (Figure 4). No significant difference was found in 
comparison to untreated cells (P < 0.05). This suggests no cytotoxicity due to ATPS treatment 
or Ad infection, including AdV purified direct from cell lysates.  
 
 
Figure 3. Analysis of AdV recovery direct from 293T cell lysates (a). Infection of HepG2 
and IMRS2 cells using AdVRSVβgal purified directly from 293T cell lysate using 3 ATPS 
formulations. Infection of AdV was characterised by staining for β- galactosidase activity. (b). 
Quantification of HepG2 and IMRS2 cell infection by AdV purified directly from 293T cell 
lysate. The upper phase presented the highest recovery of AdVRSVβgal particles and was used 
for infection. For HepG2 and IMRS2 cells, respectively, 93.3 ± 0.9% and 85.3 ± 1.8% cells 
were infected using PEG1000/K2HPO4. 91.7 ± 2.4% and 30.0 ± 1.2% cells stained positive for 
AdV infection using PEG8000/K2HPO4. 91.3 ± 1.5% and 93.7 ± 2.2% cells were infected using 








Figure 4. Analysis of cell survival after AdV/ATPS treatments. Percentage cell survival 
after treatment with upper phase ATPS +/- AdVRSVβgal.  HepG2 cells + ATPS only (dark 
grey), + CsCl AdV (light grey) and + 293T AdV (hash). PEG1000/K2HPO4 treatment showed 
viability of 77.33 ± 5.06% (+ ATPS), 90.502.88) (+ CsCl AdV ATPS) and 93.25 ± 0.63% (+ 
293T AdV). Cells treated with PEG8000/K2HPO4 upper phase showed a viability of 87.25 ± 
4.40% (+ ATPS), 92.20 ± 2.99% (+ CsCl AdV) and 91.00 ± 1.83% (+ 293T AdV). 
PEG600/(NH4)2SO4 upper phase treatment showed a viability of 83.75 ± 4.12% (+ ATPS), 
93.50 ± 0.99% (+ CsCl AdV) and 90.25 ± 1.49% (+ 293T AdV). No significant difference in 
viability was observed (P < 0.05). This demonstrates the low toxicity of ATPS subsequent to 
AdV purification and recovery (n = ≥4). 
 
3.4. In vivo application of AdCMVLuc 
In vivo gene transfer was examined 3 days post injection of ATPS purified AdV (Figure 
5). None of the treated mice (n = 3 each) displayed adverse reaction to vector injection, whilst 
displaying robust luciferase reporter expression. Levels of gene expression using ATPS 





























Figure 5. Application of PEG600/(NH4)2SO4 ATPS purified AdVLuc in vivo. AdVLuc 
virus was purified using PEG600/(NH4)2SO4 ATPS or CsCl ultracentrifugation. 1 x 10
9 
vg/ml 
AdVluc particles recovered from the ATPS upper phase or CsCl were injected into CD-1 
mice via their tail vein mice to determine in vivo gene transfer. Imaging for luciferase activity 
showed gene expression was comparable between the ATPS and CsCl purified vector thus 
demonstrating ATPS AdV can be used successfully in vivo without obvious side effects (a 
single representative mice of n = 3 shown only). 
 
4. Discussion 
AdVs are important gene transfer vectors that are under development as licensed 
bioproducts for therapeutic applications including gene therapy of genetic diseases, vaccination 
or ‘virotherapy’. They are being developed for human diseases that are hereditary or acquired 
(Albertsson, Andersson et al. 1982; Oelmeier, Dismer et al. 2011, McNally; Darling et al. 
 
2014,) and preclinical studies have been initiated using these potentially therapeutic 
pharmaceuticals in a large number of laboratories (Rogers, Bond et al. 1996; Nemunaitis, 
Ganly et al. 2000; Oelmeier, Dismer et al. 2011; Clifton 2012; Yan, Cao 2012;  Guo, Xiao et 
al. 2013; Tan, Wang et al. 2015; Molino, Lopes et al. 2018). To service intensive clinical 
studies, manufacture requires cGMP production of large quantities of recombinant virus 
vectors, often in excess of 1015 virus particles even for early phase clinical trials. Human AdV 
(hAdV) based vaccines have entered human trials against various pathogens but as hAd5 
vaccines are recognised by pre-existing immune response in humans, novel AdV from different 
species have been developed (Baden, Liu et al. 2015; Cheng, Wang et al. 2015). hAdV5, 
hAdV26 and AdVs based on chimpanzee and gorilla adenoviruses are in clinical trials, 
including to combat the COVID-19 pandemic (Baden, Liu et al. 2015; Cheng, Wang et al. 
2015; Bos, Rutten et al. 2020; Capone, Raggioli et al. 2020; Folegatti, Ewer et al. 2020; Zhu, 
Li et al. 2020). Such a variety of AdVs with differing complex surface topologies will require 
suitable manufacturing processes for their production at large scale. For example, the enormous 
challenge to meet the world-wide demand to vaccinate against COVID-19 is estimated to be 
1.76 x 1019 particles (Vellinga, Smith et al. 2014) and therefore rapid and cost effective 
alternatives to current manufacturing would be highly beneficial.  
To generate high titre AdV on a small scale or from large-scale fed-batch cultures of 
anchorage independent producer cells, cells are transfected with plasmids carrying the cis and 
trans elements required for particle production or infected with attenuated replication defective 
particles obtained directly from cell lysates or purified AdV. This production generates AdV 
RVSS for direct non-clinical use and usually is purified by CsCl buoyancy ultracentrifugation. 
AdV are then characterised and subsequently amplified to produce MVSS to be used in large 
scale downstream processing.  
Before cell lysates can be used, they require filtration. These lysates are often 
contaminated with small cellular proteins or producer cell DNA. This can reduce producer cell 
infection and can result in the blockage of columns that are used in the filtration step prior to 
further purification. For downstream purification, although CsCl buoyancy ultracentrifugation 
is regarded to be an excellent method, this requires two rounds of ultracentrifugation and 
dialysis to remove this toxic salt, which is costly and time consuming. It also reduces particle 
yield and can result in particle aggregation thereby reducing viable infectious titre yield 
(Berkner 1988; Baden, Liu et al. 2015; Cheng, Wang et al. 2015). Chromatographic methods 
over packed columns are also used to purify lysed cell samples, however these limit supernatant 
 
volumes and can also become clogged (Berkner 1988). For clinical production of AdV, 
purification is achieved via ultrafiltration using tangential flow filtration followed by anion 
exchange and then further chromatographic steps.  
Importantly, if the RVSS AdV particles required are relatively clear of cellular 
contaminants then downstream processing to MVSS would be more cost effective. To avoid 
the use of crude contaminated cell lysates or expensive and time consuming CsCl purification, 
we sought an alternative rapid, cost effective and simple method to generate RVSS AdV stocks 
for characterisation to MVSS. We also considered that this method should be amenable to 
provide AdV particles at a scale for downstream processing to high titre and infectious MVSS 
and WVSS AdV. ATPS technology has been shown successful to rapidly purify several types 
of biomolecules including proteins using immiscible liquids as phases for partitioning and 
permanent separation (Albertsson, Andersson et al. 1982). Its system provides an effective 
purification method, producing a relatively pure product with little to no need for dialysis. 
Moreover, it is an environmentally friendly, cost effective and easily scalable method that has 
been previously shown as an alternative methodology for rapid scale-up of AdV preparations, 
whilst retaining particle infectivity and titre. PEG has been found especially useful in 
separating biomolecules and its hydrophobicity is directly correlated to its molecular weight. 
When combined with a kosmotropic salt, such as PEG300-phosphate ATPS, highly infectious 
AdV partitioning occurs in the upper aqueous phase (Negrete, Ling et al. 2007a; Negrete, Ling 
et al. 2007b). Also, several polymers have been shown useful to generate concentrated viable 
virus particles using low-speed short centrifugation times. Sodium dextran sulphate is 
particularly useful because it allows salt removal from virus suspensions via precipitation, 
further concentrating virus stocks that are pure, viable are almost totally devoid of aggregates 
and dextran can also be precipitated from virus preparations (Negrete, Ling et al. 2007a; 
Negrete, Ling et al. 2007b; Oelmeier, Dismer et al. 2012; Yan, Cao 2012; Tan, Wang et al. 
2015). ATPS partitioning of adeno-associated vector (AAV) has also been shown using 10% 
PEG8000/13.2% (NH4)2SO4 solutions circumventing dialysis to generate particles pure enough 
for in vivo gene transfer  (Rogers, Bond et al. 1996; Guo, Xiao et al. 2013). 
To explore further the suitability of ATPS technology to generate effective AdV RVSS 
we tested several immiscible liquid compound formulations for their effectiveness in 
partitioning AdV particles from infected HEK293T producer cells lysates. To test vector yield 
from 9 polymer/salt combinations, CsCl purified vector was firstly partitioned between these 
ATPS immiscible phases. Of these, 3 ATPS; 14%/14% (w/w) PEG1000/K2HPO4, and 
 
14%/14% (w/w) PEG8000/K2HPO4 and 20%/20% (w/w) PEG600/(NH4)2SO4 provided 
improved, high yield recovery above those previously described, of between 47-83%. Particles 
appeared partitioned mainly in the upper, PEG rich phase and efficiently infected HepG2 cells 
with no observable cytotoxicity, with the most effective ATPS being PEG600/(NH4)2SO4. 
Using this optimal system, the quantities required for early phase clinical trials is estimated at 
1 x 1015 virus AdV particles, which would require a volume of 350ml. ATPS can be scalable 
up to 2 litre batches, enough to easily achieve this estimate (Negrete, Ling et al. 2007b). Each 
ATPS was next used to directly partition AdV particles from 293T cell lysates. While the T 
antigen is undesirable in GMP manufacture of AdV vectors, this study shows improved proof 
of concept that these ATPS are useful for processing of high titre AdVs to RVSS. All three 
ATPS appeared to partition AdV particles, with the majority of high titre preparations in the 
upper aqueous phases. Infection of HepG2 and IMRS2 reached 93.3 ± 0.9% and 85.3 ± 1.8% 
using PEG1000/K2HPO4, 91.7 ± 2.4% and 30 ± 1.2% using PEG8000/K2HPO4 and 91.3 ± 
1.5% versus 93.7 ±2.2% with PEG600/(NH4)2SO4 for each cell line respectively, closely 
matching that of infection with CsCl purified vector partitioned through ATPS.  
Vector purity is most important to avoid cytotoxicity, so to investigate whether any of 
the three ATPS or ATPS partitioned AdV cause cytotoxic side effects, each cell line was 
infected, and cell viability measured. Each ATPS alone or AdV particles purified by CsCl or 
direct from 293T cell lysates when used to infect each cell line showed no toxicity, viabilities 
between approximately 90 – 94%, with PEG600/(NH4)2SO4 partitioned vector being the 
highest. When using PEG600/(NH4)2SO4 partitioned AdV carrying the luciferase gene to inject 
CD-1 mice via the tail vein, no adverse effects were observed when compared with animals 
infected by CsCl purified AdV.  
PEG600 is commonly used in a clinical setting as an emulsifier, in ointments and 
toothpastes. The concentration of PEG600 used throughout this study remained within IGD 
limits and can be readily cleared by the kidneys or oxidised to form acidic metabolites (D'souza, 
Shegokar 2016). 
We propose that ATPS methodology partitions AdV particles highly efficiently. It also 
offers a simple, scalable procure and long-term storage with low toxicity and high yield. 
Importantly, it avoids the need for expensive equipment and costly reagents for the production 
of RVSS Ad or stocks for characterisation to MVSS/WVSS and clinical grade AdV. AdV 
particles purified to high yields through the upper phase of PEG600/(NH4)2SO4 ATPS can be 
used readily for in vitro and in vivo gene transfer. These products may be used to enter 
 
downstream processing for clinical production. ATPS is suitable to economies hoping to 
generate large amounts of AdV stocks for processing to generate Ad based vaccines against 
COVID-19. 
5. Conclusion 
The results of this study show that 20%/20% (w/w) PEG600/(NH4)2SO4 provided up to 
97 ± 3% recovery yields of Ad particles by high-level partitioning of quality vector direct from 
producer cell lysates for in vitro and in vivo gene transfer. AdV can be produced in this way at 
high titre, devoid of aggregates and can be frozen for long-term storage without loss of 
viability. Viable particles are effective for gene transfer both in vitro and in vivo without 
obvious cytotoxic effects. As ATPS technology is readily scalable, without the need for 
expensive high-end equipment, it will be highly useful to generate RVSS of AdV for 
MVSS/WVSS characterisation and transport to centres throughout the world hoping to 
generate these particles as vaccines to counteract the coronavirus pandemic.  
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